Overall, intracranial objective response rates (icORR) of BM in patients with EGFR-mutated NSCLC for erlotinib and gefitinib largely range from 60%-80%, and disease control rates are higher at 80-100% (Table 1) (28–35). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.